M. Kraus & CO Bristol Myers Squibb CO Transaction History

M. Kraus & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 10, 2024	SELL	$47.98 - $54.4 $11,515 - $13,056	-240 Reduced 5.31%	4,279 $232,000
Q4 2023 Jan 10, 2024	SELL	$48.48 - $57.85 $27,100 - $32,338	-559 Reduced 11.01%	4,519 $231,000
Q3 2023 Oct 16, 2023	SELL	$57.89 - $64.73 $20,261 - $22,655	-350 Reduced 6.45%	5,078 $294,000
Q2 2023 Jul 14, 2023	SELL	$63.71 - $70.74 $76,961 - $85,453	-1,208 Reduced 18.2%	5,428 $347,000
Q1 2023 Apr 18, 2023	BUY	$65.71 - $74.53 $591 - $670	9 Added 0.14%	6,636 $459,000
Q4 2022 Jan 25, 2023	BUY	$68.48 - $81.09 $150,245 - $177,911	2,194 Added 49.49%	6,627 $0
Q3 2022 Oct 27, 2022	BUY	$0.13 - $76.84 $103 - $61,087	795 Added 21.85%	4,433 $315,000
Q1 2022 Apr 18, 2022	BUY	$61.48 - $73.72 $223,664 - $268,193	3,638 New	3,638 $266,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of M. Kraus & CO, based on Form 13F filings with the SEC.

Stay updated on M. Kraus & CO with notifications on news.